148 related articles for article (PubMed ID: 12484345)
1. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients.
Maes BD; Lemahieu W; Kuypers D; Evenepoel P; Coosemans W; Pirenne J; Vanrenterghem YF
Am J Transplant; 2002 Nov; 2(10):989-92. PubMed ID: 12484345
[TBL] [Abstract][Full Text] [Related]
2. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
3. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
4. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group.
Laskow DA; Vincenti F; Neylan JF; Mendez R; Matas AJ
Transplantation; 1996 Oct; 62(7):900-5. PubMed ID: 8878381
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin inhibitors in pediatric renal transplant recipients.
Filler G
Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
[TBL] [Abstract][Full Text] [Related]
6. [Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction].
Cofán F; Gutiérrez R; Beardo P; Campistol JM; Oppenheimer F; Alcover J
Nefrologia; 2002; 22(5):470-6. PubMed ID: 12497749
[TBL] [Abstract][Full Text] [Related]
7. Increased tacrolimus trough levels in association with severe diarrhea, a case report.
Asano T; Nishimoto K; Hayakawa M
Transplant Proc; 2004 Sep; 36(7):2096-7. PubMed ID: 15518758
[TBL] [Abstract][Full Text] [Related]
8. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group.
Mayer AD; Dmitrewski J; Squifflet JP; Besse T; Grabensee B; Klein B; Eigler FW; Heemann U; Pichlmayr R; Behrend M; Vanrenterghem Y; Donck J; van Hooff J; Christiaans M; Morales JM; Andres A; Johnson RW; Short C; Buchholz B; Rehmert N; Land W; Schleibner S; Forsythe JL; Talbot D; Pohanka E
Transplantation; 1997 Aug; 64(3):436-43. PubMed ID: 9275110
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
Miller J; Mendez R; Pirsch JD; Jensik SC
Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
[TBL] [Abstract][Full Text] [Related]
10. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.
Pirsch JD; Miller J; Deierhoi MH; Vincenti F; Filo RS
Transplantation; 1997 Apr; 63(7):977-83. PubMed ID: 9112351
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients.
Takahara S; Kokado Y; Kameoka H; Takano Y; Moutabarrik A; Jiang H; Ishibashi M; Okuyama A; Nishi Y; Chiba N
Transplant Proc; 1994 Oct; 26(5):2802-6. PubMed ID: 7524219
[No Abstract] [Full Text] [Related]
13. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
[TBL] [Abstract][Full Text] [Related]
14. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis.
Internation Neoral Renal Transplantation Study Group
Am J Transplant; 2002 Feb; 2(2):157-66. PubMed ID: 12099518
[TBL] [Abstract][Full Text] [Related]
15. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
16. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
Lam H; Jeffery J; Sitar DS; Aoki FY
Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
[TBL] [Abstract][Full Text] [Related]
17. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients.
Sato K; Amada N; Sato T; Miura S; Ohashi Y; Sekiguchi S; Satomi S; Okazaki H
Clin Transplant; 2004 Oct; 18(5):585-90. PubMed ID: 15344965
[TBL] [Abstract][Full Text] [Related]
18. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
[TBL] [Abstract][Full Text] [Related]
19. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
20. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection.
Yamani MH; Starling RC; Goormastic M; Van Lente F; Smedira N; McCarthy P; Young JB
Transplantation; 2000 Jun; 69(11):2326-30. PubMed ID: 10868634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
